Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.41

Mkt cap

4.7M

Volume

479K

High

0.41

P/E Ratio

N/A

52-wk high

32.70

Low

0.37

Div yield

N/A

52-wk low

0.37

TC BioPharm (NASDAQ: TCBP) plans to start preclinical studies for its lead therapeutic TCB008 targeting H5N1, or Bird Flu. The company is seeking university partners to accelerate the process towards a Phase I study.

Portfolio Pulse from

January 15, 2025 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) will present at the Sequire Investor Summit 2025, where CEO Bryan Kobel will provide a corporate overview. The event is scheduled for January 21-23, 2025, in San Juan, Puerto Rico.

Portfolio Pulse from

January 13, 2025 | 2:00 pm

TC BioPharm (NASDAQ: TCBP) announced that its American Depository Shares continue to trade on the Nasdaq Global Select Market without any interruptions. The company is a clinical-stage biotechnology firm focusing on gamma-delta T cell therapies for cancer.

Portfolio Pulse from

January 06, 2025 | 6:45 pm

TC BioPharm (NASDAQ: TCBP) is advancing negotiations with two acquisition candidates as part of its M&A strategy to expand its therapeutic platform.

Portfolio Pulse from

December 31, 2024 | 3:30 pm

TC BioPharm (NASDAQ: TCBP) has announced a 25% stock dividend, which was approved at the company's General Meeting. This move is part of the company's strategy as a clinical-stage biotechnology firm.

Portfolio Pulse from

December 30, 2024 | 3:45 pm

TC BioPharm (NASDAQ: TCBP) has completed the final dosing of 3 patients in its ACHIEVE Phase 2b clinical trial for TCB008, targeting AML and MDS/AML. No drug-related adverse events were reported, indicating a positive step in the trial's progress.

Portfolio Pulse from

December 20, 2024 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) has announced a general meeting to approve a special dividend of 0.25 ADSs per 1 ADS held. This decision is pending shareholder approval.

Portfolio Pulse from

December 18, 2024 | 1:45 pm

TC BioPharm partners with CareDx to use AlloCell for pharmacokinetic monitoring in the ACHIEVE clinical trial, focusing on allogeneic gamma-delta T cell therapies for AML and MDS.

Portfolio Pulse from

December 11, 2024 | 12:15 pm

TC BioPharm (NASDAQ: TCBP) announced a positive update on their ACHIEVE UK clinical trial, with promising safety data allowing for higher doses of TCB008. The trial is progressing with four UK sites recruiting patients and two more expected by H1 2025.

Portfolio Pulse from

December 04, 2024 | 1:45 pm

TC BioPharm (NASDAQ: TCBP) has received $250,000 in non-dilutive funding from the G-Rex® Grant Program, a $20M initiative by ScaleReady, Wilson Wolf Manufacturing, and Bio-Techne Corporation to advance cell and gene-modified cell therapy development.

Portfolio Pulse from

November 12, 2024 | 2:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.